Congratulations to BCW member Sapience Therapeutics, Inc. that has been awarded a Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant is to investigate the inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide. The grant will provide funds over two years to support the discovery and development of peptide therapeutics against coronaviruses, including SARS-CoV-2 (COVID-19).
“We are very excited to have received this grant from the NIAID/NIH, which will allow us to investigate the potential of our platform for targeting SARS-CoV-2 while remaining focused on our goal to address difficult to treat cancer indications,” said Jim Rotolo, Ph.D., VP, Translational Pharmacology and Head of Research of Sapience Therapeutics.
The Harrison-based biotech is focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications. The privately held company is headed by President and CEO Barry Kappel, Ph.D., MBA.